Overview of the RATIFY study: midostaurin combination therapy for AML - 101793

Spotlight
Video

Overview of the RATIFY study: midostaurin combination therapy for AML

VJHemOnc has 1608 videos Subscribe Here

Loading........
Description: In this interview, Richard Stone, MD, of the Dana-Farber Cancer Institute, Boston, MA, provides an overview of the Phase III RATIFY study (NCT00651261) of daunorubicin, cytarabine and midostaurin for the treatment of newly diagnosed acute myeloid leukemia (AML). Dr Stone highlights the implications of this regimen for the treatment of FLT3-mutated AML. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Shared By : VJHemOnc
Posted on : 01/17/18
Added : 11 months ago